# Universidad Mayor

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/universidad-mayor/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 57 |
| Citations | 297,651 |
| City | Santiago |
| Country | CL |
| Description | Universidad Mayor is a research organisation in Santiago, CL. OpenAlex records 8,785 works and 297,651 citations for it. 2,996 researchers list it as their most recent affiliation. |
| Homepage | https://www.umayor.cl |
| OpenAlex ID | https://openalex.org/I116419501 |
| Researchers | 2,996 |
| ROR ID | https://ror.org/00pn44t17 |
| Type | education |
| Wikidata ID | https://www.wikidata.org/wiki/Q29731 |
| Works | 8,785 |

## University papers

- [Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial](https://scholariq.org/papers/pembrolizumab-versus-docetaxel-for-previously-treated-pd-l1-positive-advanced/)
- [Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial](https://scholariq.org/papers/dulaglutide-and-cardiovascular-outcomes-in-type-2-diabetes-rewind-a-double-blind/)
- [Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/rivaroxaban-with-or-without-aspirin-in-patients-with-stable-peripheral-or/)
- [Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/rivaroxaban-with-or-without-aspirin-in-patients-with-stable-coronary-artery/)
- [Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-versus-placebo-plus-chemotherapy-for-her2/)
- [Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial](https://scholariq.org/papers/dulaglutide-and-renal-outcomes-in-type-2-diabetes-an-exploratory-analysis-of-the/)
- [Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-lenvatinib-plus-placebo-for-advanced/)

## University top topics

Showing 8 of 23.

- [Health and Lifestyle Studies](https://scholariq.org/topics/health-and-lifestyle-studies/)
- [Ecology and Vegetation Dynamics Studies](https://scholariq.org/topics/ecology-and-vegetation-dynamics-studies/)
- [Plant and animal studies](https://scholariq.org/topics/plant-and-animal-studies/)
- [Sports Performance and Training](https://scholariq.org/topics/sports-performance-and-training/)
- [Plant Water Relations and Carbon Dynamics](https://scholariq.org/topics/plant-water-relations-and-carbon-dynamics/)
- [Aging, Health, and Disability](https://scholariq.org/topics/aging-health-and-disability/)
- [Tree-ring climate responses](https://scholariq.org/topics/tree-ring-climate-responses/)
- [Anesthesia and Sedative Agents](https://scholariq.org/topics/anesthesia-and-sedative-agents/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.